India | ABSCH-IRCC-IN-260277 | Internationally Recognized Certificates of Compliance | Access and Benefit-Sharing Clearing-House

Loading...
  |  

Internationally Recognized Certificates of Compliance (IRCC)

See amendment history for more information.

last updated: 28 Apr 2022
General Information
ABSCH-IRCC-IN-260277-1
- Competent National Authority: | ABSCH-CNA-IN-202013-2
Competent National Authority:
National Biodiversity Authority ()
5th Floor, TICEL Biopark, CSIR Road, Taramani
Chennai, Tamilnadu
600 113, India
Phone: +91 44 2254 2777,
Fax: +91 44 2254 1200,
Details of the permit or its equivalent
India/NBA/Appl/9/3746
Application in Form-III for seeking approval for the invention on “ Cytotoxic Effect of Novel Thermostable Protease Purified from Ginger (Zingiber officinale var. rejatha) on MCF-7; Human Breast Cancer Cell Line ” for obtaining IP rights in India.
Indian Patent Application No.- 201711024349
31 Mar 2022
Prior Informed Consent (PIC) Information
Yes
- Competent National Authority: | ABSCH-CNA-IN-202013-2
Competent National Authority:
National Biodiversity Authority ()
5th Floor, TICEL Biopark, CSIR Road, Taramani
Chennai, Tamilnadu
600 113, India
Phone: +91 44 2254 2777,
Fax: +91 44 2254 1200,
Confidential information
Confidential information
Mutually Agreed Terms (MAT) Information
Yes
1. The user shall notify NBA within 60 days from the date of grant of IPR and also assignment or license of the IPR if any, to any person. 
2. If the user himself commercializes the process/product/innovation, the monetary sharing shall be 0.4% on the annual gross ex-factory sale minus government taxes. 
3. The user shall inform NBA about any commercialization made on the IP Rights.
4. The user shall submit annual report to NBA as per the terms and conditions agreed upon. 
Subject-matter or genetic resource(s)
Confidential information


Information on the utilization of the genetic resource(s)
Confidential information
1. If the user assigns/licenses the process/product/innovation to a third party for commercialization, the user shall pay to NBA 4.0% of the fee received (in any form including the license / assignee fee) and 4.0% of the royalty amount received annually from the assignee/licensee. 
                                                                                         
2. In case the user assigns or transfers the IPR in whole or in part to any person, whether voluntarily or involuntarily, the user undertakes to attach this agreement as an appendix to the assignment instrument which shall be binding upon such person. 
Additional Information
Amendment history
Unique identifier Status Date
ABSCH-IRCC-IN-260277-1
REVOKED OLD VERSION PUBLISHED DELETED
S. Kerketta (s.kerketta66@gov.in)
28 Apr 2022 12:27
on 28 Apr 2022 12:27